Pfizer gains on transferring Upjohn business to Mylan Pharmaceuticals for Rs 180.48 crore
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Pfizer is currently trading at Rs. 4250.00, up by 30.20 points or 0.72% from its previous closing of Rs. 4219.80 on the BSE.
The scrip opened at Rs. 4240.00 and has touched a high and low of Rs. 4250.00 and Rs. 4220.10 respectively. So far 300 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6164.80 on 08-Sep-2021 and a 52 week low of Rs. 4056.00 on 29-Jun-2022.
Last one week high and low of the scrip stood at Rs. 4250.00 and Rs. 4120.45 respectively. The current market cap of the company is Rs. 19355.87 crore.
The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 17.38% and 18.70% respectively.
Pfizer has transferred its certain primarily off-patent branded and generic established medicines business (Upjohn Business) comprising of six brands which included Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin along with related business assets and liabilities to Mylan Pharmaceuticals, effective August 1, 2022. Accordingly, the Company has received the purchase consideration of Rs 180.48 crore from Mylan Pharmaceuticals. Earlier, the company had entered into a business transfer agreement (BTA) with Mylan Pharmaceuticals.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.
